Literature DB >> 31555886

Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety.

Csaba Oláh1, Zsófia Kardos2, Mónika Andrejkovics3,4, Enikő Szarka1, Katalin Hodosi5, Andrea Domján5, Mariann Sepsi6, Attila Sas7, László Kostyál6, Katalin Fazekas2, Ágnes Flórián2, Katalin Lukács2, Ágnes Miksi2, Zsuzsanna Baráth2, György Kerekes8, Márta Péntek9,10, Attila Valikovics7, László Tamási2, Dániel Bereczki11, Zoltán Szekanecz12.   

Abstract

We assessed cognitive function of female rheumatoid arthritis (RA) patients and analyze the determinants, with special focus on cerebrovascular morphology. Sixty methotrexate (MTX-) or biologic-treated RA patients and 39 healthy controls were included in a cross-sectional study. Smoking habits, alcohol intake and time spent in education were recorded. Standard measures were performed to assess cognitive function (Montreal Cognitive Assessment, MOCA; Trail Making Test, TMT; Victoria Stroop Test, VST; Wechsler Adult Intelligence Scale, WAIS; Benton Visual Retention test, BVRT), depression (Beck Depression Inventory, BDI), anxiety (State-Trait Anxiety Inventory, STAIT/S) and general health status (Short Form 36, SF-36). Mean disease activity (28-joint Disease Activity Score, mDAS28; erythrocyte sedimentation rate, mESR; C-reactive protein, mCRP) of the past 12 months was calculated; anti-cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) were assessed. Cerebral vascular lesions and atrophy, carotid intima-media thickness (cIMT) and plaques, as well as median cerebral artery (MCA) circulatory reserve capacity (CRC) were assessed by brain magnetic resonance imaging (MRI), carotid ultrasound and transcranial Doppler, respectively. Cognitive function tests showed impairment in RA vs controls. Biologic- vs MTX-treated subgroups differed in TMT-A. Correlations were identified between cognitive function and depression/anxiety tests. WAIS, STAIS, STAIT and BDI correlated with most SF-36 domains. Numerous cognitive tests correlated with age and lower education. Some also correlated with disease duration, mESR and mDAS28. Regarding vascular pathophysiology, cerebral vascular lesions were associated with VST-A, carotid plaques with multiple cognitive parameters, while MCA and CRC with MOCA, BVRT and BDI. RA patients have significant cognitive impairment. Cognitive dysfunction may occur together with or independently of depression/anxiety. Older patients and those with lower education are at higher risk to develop cognitive impairment. Cognitive screening might be a useful tool to identify subgroups to be further investigated for cerebrovascular pathologies.

Entities:  

Keywords:  Biological therapy; Carotid artery; Cerebrovascular disease; Cognitive dysfunction; Methotrexate; Rheumatoid arthritis; Transcranial Doppler

Mesh:

Substances:

Year:  2019        PMID: 31555886     DOI: 10.1007/s00296-019-04449-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  36 in total

1.  [Assessment of memory in patients with rheumatoid arthritis].

Authors:  Snezana Tomasević-Todorovic; Ksenija Bosković; Danka Filipović; Nada Naumović
Journal:  Vojnosanit Pregl       Date:  2011-06       Impact factor: 0.168

Review 2.  Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome.

Authors:  Deborah P M Symmons
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-12       Impact factor: 4.098

Review 3.  Geoepidemiology: the environment and spondyloarthropathies.

Authors:  Michael Ehrenfeld
Journal:  Autoimmun Rev       Date:  2009-12-21       Impact factor: 9.754

4.  Depressive symptoms in early rheumatoid arthritis: a comparative longitudinal study.

Authors:  Eva Palkonyai; Gernot Kolarz; Maria Kopp; Gabor Bogye; Peter Temesvari; Laszlo Palkonyay; Istvan Ratko; Eszter Meszaros
Journal:  Clin Rheumatol       Date:  2007-02-28       Impact factor: 2.980

Review 5.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Authors:  R Agca; S C Heslinga; S Rollefstad; M Heslinga; I B McInnes; M J L Peters; T K Kvien; M Dougados; H Radner; F Atzeni; J Primdahl; A Södergren; S Wallberg Jonsson; J van Rompay; C Zabalan; T R Pedersen; L Jacobsson; K de Vlam; M A Gonzalez-Gay; A G Semb; G D Kitas; Y M Smulders; Z Szekanecz; N Sattar; D P M Symmons; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2016-10-03       Impact factor: 19.103

6.  Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.

Authors:  György Kerekes; Zoltán Szekanecz; Henriett Dér; Zsuzsa Sándor; Gabriella Lakos; László Muszbek; István Csipö; Sándor Sipka; Ildikó Seres; György Paragh; János Kappelmayer; Edit Szomják; Katalin Veres; Gyula Szegedi; Yehuda Shoenfeld; Pál Soltész
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666

7.  Cognitive impairment in rheumatoid arthritis.

Authors:  S Appenzeller; M B Bertolo; L T L Costallat
Journal:  Methods Find Exp Clin Pharmacol       Date:  2004-06

8.  A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis.

Authors:  Andrew Schrepf; Chelsea M Kaplan; Eric Ichesco; Tony Larkin; Steven E Harte; Richard E Harris; Alison D Murray; Gordon D Waiter; Daniel J Clauw; Neil Basu
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 14.919

9.  Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis.

Authors:  Csaba Oláh; Zsófia Kardos; Mariann Sepsi; Attila Sas; László Kostyál; Harjit Pal Bhattoa; Katalin Hodosi; György Kerekes; László Tamási; Attila Valikovics; Dániel Bereczki; Zoltán Szekanecz
Journal:  Arthritis Res Ther       Date:  2017-09-26       Impact factor: 5.156

10.  Disease activity and cognition in rheumatoid arthritis: an open label pilot study.

Authors:  Graham Raftery; Jiabao He; Ruth Pearce; Daniel Birchall; Julia L Newton; Andrew M Blamire; John D Isaacs
Journal:  Arthritis Res Ther       Date:  2012-12-04       Impact factor: 5.156

View more
  4 in total

Review 1.  Cognitive Decline in Rheumatoid Arthritis: Insight into the Molecular Pathogenetic Mechanisms.

Authors:  Maria Sofia Basile; Rosella Ciurleo; Alessia Bramanti; Maria Cristina Petralia; Paolo Fagone; Ferdinando Nicoletti; Eugenio Cavalli
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

2.  Longitudinal Study of Cognitive Functioning in Adults with Juvenile Idiopathic Arthritis.

Authors:  Natalia Mena-Vázquez; Fernando Ortiz-Márquez; Pablo Cabezudo-García; Claudia Padilla-Leiva; Gisela Diaz-Cordovés Rego; Luis Muñoz-Becerra; Teresa Ramírez-García; Jose Manuel Lisbona-Montañez; Sara Manrique-Arija; Arkaitz Mucientes; Esmeralda Núñez-Cuadros; Rocío Galindo Zavala; Pedro Jesús Serrano-Castro; Antonio Fernández-Nebro
Journal:  Biomedicines       Date:  2022-07-18

Review 3.  Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review.

Authors:  May N Lwin; Lina Serhal; Christopher Holroyd; Christopher J Edwards
Journal:  Rheumatol Ther       Date:  2020-06-13

Review 4.  Cognitive dysfunction in autoimmune rheumatic diseases.

Authors:  Csaba Oláh; Noa Schwartz; Christopher Denton; Zsófia Kardos; Chaim Putterman; Zoltán Szekanecz
Journal:  Arthritis Res Ther       Date:  2020-04-15       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.